Research Summary

I was trained in Medical Oncology but became involved in the early AIDS epidemic in San Francisco based at San Francisco General Hospital. I have worked in clinical trials in HIV-related malignancies but primarily in the development of antiretroviral therapy. I was the PI and co-director with Warner Greene of the NIAID-funded UCSF-Gladstone Center for AIDS Research supporting the large community of HIV investigators in San Francisco. CFAR provides core services, pilot grants to early career stage investigators and supports a comprehensive mentorship program. In the Clinical and Translational Sciences Institute I served as a member of the Board of Directors and formerly directed the Global Health Program. I stepped down as the Chief of the Medical Service at the San Francisco VA Medical Center in 2012 to become the Director of the UCSF AIDS Research Institute. The ARI is the comprehensive University organization that links all HIV/AIDS research programs and is the central focus for communications, media relations and philanthropic support for this internationally recognized response to the HIV epidemic. In 2015, the ARI became the administrative home for a unique initiative to cure HIV infection funded by amfAR, the Foundation for AIDS Research. I served until recently as the Director of the amfAR Institute for HIV Cure, working with leading scientists at UCSF, the Gladstone Institute for Virology and Immunology, and the Vitalant (formerly the Blood Systems) Research Institute. I also served as the Associate Chair of the UCSF Department of Medicine for Global Health. My clinical appointment is at the VA as a retired volunteer physician where I maintain an active HIV outpatient practice. I am the Clinical Editor in Chief of the Journal of the Acquired Immunodeficiency Syndromes and served as the Chair of the Scientific Advisory Board of the Accordia Global AIDS Foundation and the Infectious Diseases Institute at Makerere University in Kampala Uganda. I was a board member of the Pangaea Global AIDS Foundation. I am an active member of the National Academy of Medicine (formerly the Institute of Medicine) of the National Academy of Sciences and am the founder and Board Chair of the International Antiviral Society-USA. On Twitter I am @pvolberding.

Research Funding

  • September 1, 2012 - August 31, 2022 - Recent Advances in AIDS and HIV Research, Principal Investigator. Sponsor: NIH/NIAID, Sponsor Award ID: R13AI102630
  • August 5, 1999 - September 29, 2012 - Cancer Center Support Grant, Co-Investigator. Sponsor: NIH/NCI, Sponsor Award ID: P30CA082103
  • October 21, 2020 - September 14, 2007 - UCSF-Gladstone Center for AIDS Research, Principal Investigator. Sponsor: NIH/NIAID, Sponsor Award ID: P30AI027763
  • December 1, 1974 - September 29, 2006 - General Clinical Research Center, Co-Investigator. Sponsor: NIH/NCRR, Sponsor Award ID: M01RR000079

Education

University of Chicago, BA, 1967-1971, Biology
University of Minnesota, MD, 1971-1975, Medicine
University of Utah Medical Center, Residency, 1975-1978, Internal Medicine
University of California San Francisco, Fellow, 1978-1981, Hematology/Oncology

Honors & Awards

  • 1986-1987
    National Academy of Sciences (Institute of Medicine) AIDS Policy Review Steering Committee
  • 1986-1987
    American Medical Association AIDS Panel
  • 1986-1988
    NIH AIDS Drug Selection Committee Member
  • 1986-1988
    National Institutes of Allergy and Infectious Disease AIDS Clinical Trials Group Executive Committee
  • 1987-1990
    National Academy of Sciences (Institute of Medicine) AIDS Activities Oversight Committee
  • 1990-1992
    International AIDS Society, President
  • 1992-1993
    Co-chair Institute of Medicine Round Table on AIDS Drug and Vaccine Development
  • 1993-present
    Founder and Board Chair, International AIDS Society - USA, Inc.
  • 1994-present
    National Policy Advisory Board for the HIV Cost and Services Utilization Study, RAND
  • 1997-present
    HIV Research Agenda Committee, AIDS Clinical Trials Group
  • 1998-present
    Interim Review Committee, ACTG 372
  • 1998-present
    Interim Review Committee, ACTG 368
  • 1998-present
    Center for AIDS Research Directors' Group, Chair
  • 1999-present
    Institute of Medicine

Selected Publications

  1. Satre DD, Levine-Hall T, Sterling SA, Young-Wolff KC, Lam JO, Alexeeff S, Hojilla JC, Williams A, Justice AC, Sterne J, Cavassini M, Bryant KJ, Williams EC, Horberg MA, Volberding P, Weisner C, Silverberg MJ The relationship of smoking and unhealthy alcohol use to the HIV care continuum among people with HIV in an integrated health care system.  View on PubMed
  2. Malekinejad M, Blodgett J, Horvath H, Parriott A, Hutchinson AB, Shrestha RK, McCabe D, Volberding P, Kahn JG Change in Condom Use in Populations Newly Aware of HIV Diagnosis in the United States and Canada: A Systematic Review and Meta-Analysis.  View on PubMed
  3. Satre DD, Parthasarathy S, Silverberg MJ, Horberg M, Young-Wolff KC, Williams EC, Volberding P, Campbell CI Health care utilization and HIV clinical outcomes among newly enrolled patients following Affordable Care Act implementation in a California integrated health system: a longitudinal study.  View on PubMed
  4. Saag MS, Gandhi RT, Hoy JF, Landovitz RJ, Thompson MA, Sax PE, Smith DM, Benson CA, Buchbinder SP, Del Rio C, Eron JJ, Fätkenheuer G, Günthard HF, Molina JM, Jacobsen DM, Volberding PA Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2020 Recommendations of the International Antiviral Society-USA Panel.  View on PubMed
  5. Volberding P Sharing Experiences and Lessons: Medical Issues in Confronting the HIV Epidemic and COVID-19.  View on PubMed
  6. Harding BN, Whitney BM, Nance RM, Crane HM, Burkholder G, Moore RD, Mathews WC, Eron JJ, Hunt PW, Volberding P, Rodriguez B, Mayer K, Saag MS, Kitahata MM, Heckbert SR, Delaney JAC Antiretroviral drug class and anaemia risk in the current treatment era among people living with HIV in the USA: a clinical cohort study.  View on PubMed
  7. Heinemann AW, Volberding PA National Academies Consensus Report on Functional Assessment for Adults With Disabilities.  View on PubMed
  8. Volberding P, Chambers HF Antimicrobial Drug Development Efficiency and Surrogate Markers of Clinical Benefit.  View on PubMed
  9. Satre DD, Anderson AN, Leibowitz AS, Levine-Hall T, Slome S, Flamm J, Hare CB, McNeely J, Weisner CM, Horberg MA, Volberding P, Silverberg MJ Implementing electronic substance use disorder and depression and anxiety screening and behavioral interventions in primary care clinics serving people with HIV: Protocol for the Promoting Access to Care Engagement (PACE) trial.  View on PubMed
  10. Scott H, Volberding PA HIV Screening and Preexposure Prophylaxis Guidelines: Following the Evidence.  View on PubMed
  11. Satre DD, Leibowitz AS, Leyden W, Catz SL, Hare CB, Jang H, Lam JO, Bryant KJ, Weisner CM, Sterling SA, Horberg M, Volberding P, Silverberg MJ Interventions to Reduce Unhealthy Alcohol Use among Primary Care Patients with HIV: the Health and Motivation Randomized Clinical Trial.  View on PubMed
  12. Chahal HS, Peters MG, Harris AM, McCabe D, Volberding P, Kahn JG Cost-effectiveness of Hepatitis B Virus Infection Screening and Treatment or Vaccination in 6 High-risk Populations in the United States.  View on PubMed
  13. Namazi G, Fajnzylber JM, Aga E, Bosch RJ, Acosta EP, Sharaf R, Hartogensis W, Jacobson JM, Connick E, Volberding P, Skiest D, Margolis D, Sneller MC, Little SJ, Gianella S, Smith DM, Kuritzkes DR, Gulick RM, Mellors JW, Mehraj V, Gandhi RT, Mitsuyasu R, Schooley RT, Henry K, Tebas P, Deeks SG, Chun TW, Collier AC, Routy JP, Hecht FM, Walker BD, Li JZ The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies.  View on PubMed
  14. Sharaf R, Lee GQ, Sun X, Etemad B, Aboukhater LM, Hu Z, Brumme ZL, Aga E, Bosch RJ, Wen Y, Namazi G, Gao C, Acosta EP, Gandhi RT, Jacobson JM, Skiest D, Margolis DM, Mitsuyasu R, Volberding P, Connick E, Kuritzkes DR, Lederman MM, Yu XG, Lichterfeld M, Li JZ HIV-1 proviral landscapes distinguish posttreatment controllers from noncontrollers.  View on PubMed
  15. Saag MS, Benson CA, Gandhi RT, Hoy JF, Landovitz RJ, Mugavero MJ, Sax PE, Smith DM, Thompson MA, Buchbinder SP, Del Rio C, Eron JJ, Fätkenheuer G, Günthard HF, Molina JM, Jacobsen DM, Volberding PA Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel.  View on PubMed
  16. Strongin Z, Sharaf R, VanBelzen DJ, Jacobson JM, Connick E, Volberding P, Skiest DJ, Gandhi RT, Kuritzkes DR, O'Doherty U, Li JZ Effect of Short-Term Antiretroviral Therapy Interruption on Levels of Integrated HIV DNA.  View on PubMed
  17. Benson CA, Currier JS, Del Rio C, Gallant JE, Gulick RM, Marrazzo JM, Richman DD, Saag MS, Schooley RT, Volberding PA A Conversation Among the IAS-USA Board of Directors: Hot Topics and Emerging Data in HIV Research and Care.  View on PubMed
  18. Malekinejad M, Parriott A, Blodgett JC, Horvath H, Shrestha RK, Hutchinson AB, Volberding P, Kahn JG Effectiveness of community-based condom distribution interventions to prevent HIV in the United States: A systematic review and meta-analysis.  View on PubMed
  19. Volberding PA How to Survive a Plague: The Next Great HIV/AIDS History.  View on PubMed
  20. Volberding PA HIV Treatment and Prevention: An Overview of Recommendations From the IAS-USA Antiretroviral Guidelines Panel.  View on PubMed

Go to UCSF Profiles, powered by CTSI